Lucid Diagnostics Inc. (LUCD) intrinsic value & 10-year financials
Lucid Diagnostics Inc. (LUCD) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 7 fiscal years revenue grew 75.2% a year to $4.7M, with an average return on invested capital of -413.1%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.48
- Market cap
- $24.1M
- Revenue (FY2025)
- $4.7M
- Revenue growth (7-yr CAGR)
- 75.2%
- ROIC (10-yr avg)
- -413.1%
- Free cash flow (FY2025)
- -$46.7M
LUCD 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $4.7M | -$58.0M | — | -$46.7M | -1054.8% | 261.2% |
| FY2024 | $4.3M | -$45.5M | -$1.05 | -$44.4M | -1059.6% | 254.6% |
| FY2023 | $2.4M | -$52.7M | -$1.26 | — | -1996.8% | 543.0% |
| FY2022 | $377.0K | -$56.2M | -$1.55 | -$32.9M | -14899.5% | -3488.9% |
| FY2021 | $500.0K | -$28.1M | — | -$18.5M | -5483.8% | -136.2% |
| FY2020 | — | -$8.3M | — | — | — | 88.0% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Lucid Diagnostics Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Lucid Diagnostics Inc. has historically struggled to out-earn its cost of capital, averaging just -12.1% ROIC.
Lucid Diagnostics Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Lucid Diagnostics Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-38.14 per share.